The Expression Level of CCDC26 and FOXCUT Genes in Acute Lymphoblastic Leukemia by Barati, Samaneh et al.
AMLS Archives of Medical Laboratory Sciences 
Archives of Medical Laboratory Sciences; Volume 7, 2021 (Continuous Volume)  1 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License  
Original Article 
The Expression Level of CCDC26 and FOXCUT Genes in Acute 
Lymphoblastic Leukemia 
Samaneh Barati1, Seyed Hadi Mousavi1*, Jamal Motallebzadeh-Khanmiri1, Mohammad Khani-Eshratabadi1 
1. Department of Hematology and Blood Transfusion, School of Allied Medical Sciences, Tehran University of 
Medical Sciences, Tehran, Iran. 
Received: January 3, 2021, 2021; Accepted: February 27, 2021 
Abstract 
Background and Aim: Acute lymphoblastic leukemia (ALL) is a malignant disease of lymphoid progenitor cells 
affecting both children and adults. Long non-coding RNAs (lncRNAs) are one kind of non-coding RNAs (ncRNAs), 
reported modulating the initiation or progression of diverse cancers. However, the role of CCDC26 and FOXCUT 
long non-coding RNAs in ALL has been unknown. In this study, we explored the expression of FOXCUT and 
CCDC26 lncRNAs in acute lymphoblastic leukemia cell lines. 
Methods: Acute T lymphoblastic leukemia cell lines, RPMI 8402, Jurkat, B lymphoblastic leukemia, Daudi, and 
Ramos cell lines were used. After culturing the cells, RNA extraction and cDNA synthesis were performed. The real-
time PCR technique was then used to study the expression of CCDC26, FOXCUT, C-kit, and FOXC1 genes. 
Result: We found a significant increase of CCDC26 expression in RPMI 8402 (p <0.0001) and Ramos (p <0.05) cell 
lines compared to the control, while decreased expression of these genes was observed in Jurkat and Daudi cell lines. 
Furthermore, FOXCUT gene had a significant increase in expression in all cell lines compared to the control (p <0.01 
in Daudi and RPMI 8402 cell lines) (p <0.001 in Jurkat and Ramos cell lines). 
Conclusion: Our results demonstrated that CCDC26 and FOXCUT genes can play a regulatory role in acute 
lymphoblastic leukemia and may serve as a potential diagnostic biomarker and therapeutic target of acute 
lymphoblastic leukemia. 
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Acute lymphoblastic leukemia (ALL) is caused by a 
multistage somatic mutation in a single B or T 
lymphoid progenitor cell, occurring in one of the 
stages of development. The proliferation and 
accumulation of clonal blast cells in the bone 
marrow inhibits hematopoiesis and finally leads to 
anemia, neutropenia, and thrombocytopenia (1, 2). 
ALL is one of the most common and severe-to-treat 
childhood malignant neoplasia, accounting for 25% 
of all cancers in children under the age of 15 and 
also includes 20% of acute leukemia in adults (3, 
4).  
In the United States, more than 5900 patients are 
diagnosed with ALL, 25% of whom die annually 
(5). Despite clinical advancement in ALL diagnosis 
and treatment, patients with ALL, especially those 
with refractory or relapsed forms, still suffer from 
poor prognosis, severe adverse events, and low 
survival rate (6). It is thus essential to understand 
the underlying signaling pathways of ALL 
pathogenesis, development, metastasis, and death, 
to identify a new biomarker for ALL diagnosis and 
novel molecular targets for ALL treatment (7, 8). 
Numerous agents are involved in the development, 
prognosis, and treatment of Patients with ALL. 
Among the cases that have been recently studied in 
some cancers are long non-coding RNAs 
The Expression Level of CCDC26 and FOXCUT Genes …                                                                       Barati S, et al. 
Archives of Medical Laboratory Sciences; Volume 7, 2021 (Continuous Volume)  2 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License 
(lncRNAs). Some studies have shown that lncRNAs 
have a significant effect on cell death and cell 
growth by controlling apoptosis in solid tumors, 
leukemias, and gliomas. Long non-coding RNAs 
(lncRNAs) have recently been studied in some 
cancers (9, 10). Some studies have shown that 
lncRNAs have a significant effect on cell death and 
cell growth by controlling apoptosis in solid tumors, 
leukemias, and gliomas(11). lncRNAs are mRNA-
like transcripts, ranging in size from 200 
nucleotides to 100 kb. All but a few are locking the 
ability to synthesize proteins(12). Some studies on 
the role of lncRNAs indicate that their control 
mechanisms are complex in regulating the pattern 
of gene expression, involved in regulating gene 
expression at the transcriptional and post-
transcriptional levels (13). For example, 
transcriptional regulation involves the epigenetic 
inactivation of some genes, but post-transcriptional 
regulation by lncRNAs involves several factors(14). 
FOXCUT is located on chromosome 6 and is 
transcribed from upstream of the FOXC1 promoter, 
which is why it is called FOXC1 upstream promoter 
transcript (15). FOXC1 is a member of the 
Forkhead family, which is an important 
transcription factor in regulating a variety of 
biological processes, including tumorigenesis and 
cell migration. FOXC1 is also associated with 
invasive phenotypes and increased cell proliferation 
in lung cancer cells. An increase of FOXC1 has 
been reported in approximately 20% of AML 
samples, which is a barrier to 
monocyte/macrophage differentiation and increases 
the clonogenic potential of AML cells. Silencing of 
FOXCUT reduces the expression of FOXC1. 
Silencing both FOXCUT and FOXC1 genes 
reduces cell proliferation and cell migration. 
FOXC1 is involved in four important biological 
processes (proliferation, tumorigenesis, metastasis, 
and angiogenesis) (16, 17).  
CCDC26 is located on chromosome 8 (24q8), and 
its protein contains 109 amino acids. Despite the 
ambiguous nature of CCDC26 function as an 
oncogene or anti-oncogene, there is considerable 
evidence of CCDC26 association with specific 
tumors, including glioma and AML, in which an 
increase in all or part of the CCDC26 genetic locus 
has been observed in children with acute leukemia 
(18). CCDC26 also appears to control growing 
myeloid leukemia cells by regulating kit gene 
expression. However, the role of lncRNAs in the 
ALL cell line has not been investigated(19). 
There is currently no extensive evidence on the 
function of CCDC26, and it is yet to be known. 
CCDC26 is located on chromosome 8 (24q8), and 
its protein contains 109 amino acids; however, its 
mRNA is encoded, and this protein has no 
resemblance to known proteins. Moreover, some 
studies have suggested an association between 
CCDC26 and cancers, including acute myeloblastic 
leukemia (AML) and glioma(19). The C-kit or 
CD117 is a cytokine receptor located on 
chromosome 4 (4q13) which is expressed on the 
surface of hematopoietic stem cells (HSCs) as well 
as other cells. Changed forms of this receptor may 
be related to cancer types. The binding of the C-Kit 
to its receptor on HSCs activates the C-Kit, 
resulting in autophosphorylation and initiation of 
message transmission, which as a result, leads to 
cell survival, migration, and cell proliferation. With 
the CCDC26 gene silencing, an increased 
expression is seen in the tyrosine kinase receptor. 
Kit tyrosine kinase receptors cause the survival of 
cancer cells in HSCs. CCDC26, therefore, appears 
to be a tumor suppressor non-coding RNA because 
its expression suppresses the expression of the C-
Kit gene. According to studies on the K562 cell 
line, inhibiting the expression of the CCDC26 gene 
appears to inhibit cell death and cause increased cell 
survival. Also, in cell lines in which CCDC26 is 
silenced, kit gene overexpression is seen. Kit 
Protein is important for the self-renewal and 
maintenance of HSCs. In leukemia, CSCs remain at 
this stage and cause malignancy. Therefore, it is 
possible to suppress the tumor via inhibiting or 
reducing the expression of the kit gene by CCDC26 
(17, 19). 
Glyceraldehyde 3-phosphate dehydrogenase is a 
glycolytic enzyme located on chromosome 12 that 
is involved in DNA repair, membrane fusion, and 
cell death. GAPDH is overexpressed in many 
human cancers, such as melanoma, and is directly 
related to tumor progression. Its glycolytic and anti-
apoptotic function helps to proliferate and protect 
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tumor cells, but under oxidative stress, GAPDH 
expression causes aging and cell death(20). 
 Considering the importance of C-Kit in adjusting 
hematopoietic stem cell signaling and also 
elucidating the role of CCDC26 in regulating the 
expression of this gene, the main purpose of this 
study is to determine the expression LncRNAs 
status of FOXCUT and CCDC26 in acute 
lymphoblastic leukemia cell line and further studies 
will be performed on samples from patients with 
ALL. If the results of in-vivo studies are similar, 
these two genes could be used to develop 
diagnostic, prognostic, and therapeutic methods for 
patients with ALL. In this experimental study, we 
investigated the expression of CCDC26, C-Kit, 
FOXCUT, and FOXC1 genes in ALL cell lines, and 
peripheral blood mononuclear cells (PBMCs) were 
used as the control group. 
Methods 
Cell culture: Acute T lymphocytic leukemia cell 
lines of RPMI 8402, Jurkat, B lymphoblastic 
leukemia, Daudi, and Ramos cell lines were 
obtained from Pasteur Institute of Iran. Cell lines 
were cultured according to ATCC instructions in 25 
ml flasks (T25) in RPMI-1640 medium enriched 
with 10% fetal bovine serum (FBS, Gibico, USA). 
During the culture period, the flask containing the 
cells was incubated in an incubator at 37 ° C 
containing 5% CO2, and the culture medium was 
changed every two days. After enough growth of 
the cells, some cells were frozen at -80 ° C and then 
stored in a nitrogen tank, and another flask was 
used for cell counting and RNA extraction. During 
culture, cell survival was assessed by slide 
hemocytometer and trypan blue. 
Isolation of PBMCs 
Peripheral blood lymphocyte cells of average 
humans were also used as a control sample. 
Initially, samples were obtained from a consenting 
healthy person without any particular disease, 
consumption. 10 ml of peripheral blood was 
collected in tubes containing EDTA, and PBMCs 
were isolated using Faicol gradient centrifugation 
according to instructions. RNA was extracted 
immediately after isolation. 
Extraction of RNA: YTZOL pure RNA 
commercial kit (Yekta Tajhez Azma, Iran) was used 
to extract RNA. First, 1 ml Trizol Reagent was 
added to the cell precipitate obtained from culture 
and immediately transferred to a freezing 
temperature of -30°C. After one hour, the sample 
was defrosted, 200 μl chloroform was added to the 
sample and it was centrifuged at 120000 g for 15 
minutes at 4°C.  
The clear supernatant was added to a microtube 
containing 500 μl of cold isopropanol and placed at 
-30°C for 10 minutes. After full shaking, the RNA 
solution and isopropanol were centrifuged and the 
supernatant was discarded.  
The RNA precipitate was washed twice with 70% 
ethanol (Adding 1 ml of 70% ethanol in every step 
and centrifugation at 10000 g for 7 minutes at 4°C).  
Finally, the RNA precipitate was solved in 20 μl of 
DEPC water and transferred to a -70°C until the 
time of the cDNA synthesis. 
cDNA synthesis: For cDNA synthesis in this study, 
a cDNA synthesis kit (Yekta Tajhez Azma, Iran) 
was used. RNase-free equipment and solutions were 
used in every step of the procedure. For each RNA 
sample, a 0.5 ml tube was selected and 6.2 μl 
template RNA, 1 μl Oligo (dt) primer, 8.9 μl DEPC 
water was added, with the final total volume of 
13.4 μl.  
After shaking and centrifuging for a short time, they 
were kept at 70° C for 5 minutes and then kept on 
ice. Then, 4 µL First Strand butter 5X, 1 dNTPs, 0.5 
RNasin, 1µL M-MLV were added to the microtube, 
which was kept 60 minutes at 42°C for reverse 
transcription, 5 minutes at 70°C, and one week at -
20° C for storage. 
Quantitative Real-time PCR: To perform the 
reaction, first, the primer was designed (Confirmed 
on Primer blast website), and the efficiency of the 
primers (Table 1) was evaluated using five 
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Table 1. The sequence of primers designed in this study 
Tm Product Size Sequence (5`to 3`) Primer Gene Symbol 
60 80 GGGCCACCGTTTGGAAAG Forward C-KIT 
60 TTACATTCAACCGTGCCATTG Reverse C-KIT 
59 86 GGCGAGCAGAGCTACTACC Forward FOXC1 
59 TGCGAGTACACGCTCATGG Reverse FOXC1 
62 84 CTAAGGACGGGGCTGAATTGG Forward FOXCUT 
62 GGCAGGCAACGTTAGTCATC Reverse FOXCUT 
60 90 AGGCCTGAGGAGAGAAGACAC Forward CCDC26 
60 AGAGCAGCCTGAAAAATGGA Reverse CCDC26 
58 87 TGCACCACCAACTGCTTAGC Forward GAPDH 
58 GGCATGGACTGTGGTCATGAG Reverse GAPDH 
 
 
The mentioned dilutions were added to Master Mix 
according to the protocol and placed in the Real-
Time device. Finally, the Ct of each concentration 
was placed in the REST2009 program, and the 
reaction efficiency of each primer was calculated. 
The Master mix used was a Taq DNA Polymerase 
2x Master MixRed-Amplicon.  
Ingredients for the reaction were 6.5 µL Master Mix 
Real-time (2x), 1 µL Primer (Forward and 
Reverse), 1 µL cDNA, and 7.5 µL DEPC Water. 
The PCR reaction was performed by a thermocycler 
with 35 cycles. All tests in this study were 
performed in triplicates. 
Statistical analysis: In this study, one-way 
ANOVA statistical analysis was performed using 
GraphPad Prism V6.07 software. Data are displayed 
as mean ± SD. The confidence interval was 95% in 
all experiments, and P values less than 0.05 were 
considered significant. In graphs, P values less 
than/equal to 0.05, 0.01, 0.001 and 0.0001 are 
shown with one star (*), two stars (**), three stars 
(***) and four stars (***), respectively. 
Results 
In this study, the quantitative expression of 
FOXCUT, FOXC1, CCDC26, and C-kit genes were 
evaluated by Real-Time PCR reaction by line-gene 
k with Takara master mix. The expression of the 
named LncRNAs was normalized using GAPDH as 
the internal control. The results of melting and 
amplification curves (linear) of FOXCUT, FOXC1, 
CCDC26, C-kit, and GAPDH (as internal control) 
transcripts were analyzed using Line Gene 
software. The standard curves of FOXCUT, 
FOXC1, CCDC26, C-kit, and GAPDH genes, show 
efficiency, R2 (correlation coefficient), line slope 
and intercept. The data obtained from the sample Ct 
were first analyzed using 2
CT−
methods. 
Increased Expression of FOXCUT and FOXC1 
Genes in Cell Lines Compared to the Control 
Group 
Comparing the expression of FOXCUT and FOXC1 
genes in the Daudi cell line shows that FOXC1 
expression (P>0.317) and FOXCUT expression 
(P<0.01) had increased expression compared to 
control, while FOXCUT expression was increased 
compared to that of FOXC1 (P<0.05). In the Jurkat 
cell line, both FOXC1 (P<0.9958) and FOXCUT 
(P<0.001) genes had increased expressions 
compared to the control group, and FOXCUT 
showed an increased expression compared to 
FOXC1 (P<0.001).  
In Ramos cell line, the expression of FOXCUT 
(P<0.001) and FOXC1 (P.V: 0.8362) genes 
increased compared to the control group, and 
FOXCUT expression was increased compared to 
FOXC1 (p <0.001). Finally, in RPMI 8402 cell line, 
FOXC1 (p = 0.999) and FOXCUT (P <0.01) genes 
had increased expressions compared to the control 
group, and FOXCUT expression was increased 
compared to FOXC1 (P<0.01). The results are 
summarized in Figure1. 
3.2. Different Expression of CCDC26 and C Kit 
Genes in Cell Lines Compared to the Control 
Group 
Comparison of CCDC26 and C-kit gene expression 
in the Daudi cell line shows that CCDC26 
expression was decreased compared to control (p 
>0.999), while C-kit expression was increased (p 
<0.05) and expression of C-kit was increased 
compared to CCDC26 (p <0.05). Besides, in the 
Jurkat cell line, CCDC26 gene expression was 
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decreased compared to control (p = 0.9974), and C-
kit gene expression was increased compared to 
control (p <0.05) and in general, C-kit gene 
expression was increased compared to that of 
CCDC26 gene (p <0.05).  
In RPMI 8402 cell line, CCDC26 gene expression 
was observed to increase compared to control 
(p<0.0001), and C-kit gene had a decreased 
expression compared to control (p >0.999), and in 
total, CCDC26 gene expression was increased 
compared to that of C-kit. (p <0.0001). Similarly, in 
the Ramos cell line, CCDC26 expression was 
increased compared to control (p <0.486), and C-kit 
expression was decreased compared to control (p 
<0.05), and CCDC26 expression was increased 
compared to C-kit expression (p <0.05). The results 





Figure1: Expression of FOXCUT and FOXC1 genes in cell lines compared to control samples. A: FOXC1 and 
FOXCUT genes had increased expressions compared to the control, and FOXCUT expression was increased 
compared to FOXC1. B: both FOXC1 and FOXCUT genes had increased expressions compared to the control, and 
FOXCUT showed an increased expression compared to FOXC1. C: FOXC1 expression and FOXCUT expression had 
increased expression compared to control, while FOXCUT expression was increased compared to that of FOXC1 . D: 
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Figure2: Expression of CCDC26 and C-kit genes in cell lines compared to control samples. A: CCDC26 
expression was decreased compared to control, while C-kit expression was increased and expression of C-kit was 
increased compared to CCDC26. B: CCDC26 gene expression was decreased compared to the control, and C-kit gene 
expression was increased compared to control, and in general, C-kit gene expression was increased compared to that 
of the CCDC26 gene. C: CCDC26 expression was increased compared to the control and C-kit expression was 
decreased compared to the control and CCDC26 expression was increased compared to C-kit expression.  D: CCDC26 
gene expression was observed to increase compared to control and C-kit gene had a decreased expression compared to 
control, and in total, CCDC26 gene expression was increased compared to that of C-kit. 
Discussion 
Acute lymphoblastic leukemia is neoplasia that 
results from multistage somatic mutations in a 
single lymphoid progenitor cell (B or T) at one of 
several stages of development. However, our 
knowledge of ALL genomics is still incomplete. 
This study was performed to answer the question of 
whether the expression of FOXCUT and CCDC26 
lncRNAs are altered in acute lymphoblastic 
leukemia. Studies on the role of lncRNAs in 
regulating the pattern of gene expression indicate 
the complexity of their control mechanisms, with 
these molecules at different levels of regulation of 
gene expression, including regulation at the 
transcriptional and post-transcriptional levels. 
Transcriptional regulation involves the role of 
lncRNAs in the epigenetic inactivation of specific 
genes. Nevertheless, post-transcriptional regulatory 
levels are affected by the action of lncRNAs. 
Research conducted by Pen et al. indicated that 
FOXCUT is a lncRNA (long non-coding RNA) on 
chromosome 6, transcribed upstream of the FOXC1 
promoter(21). FOXC1 is a crucial transcription 
factor in regulating a variety of biological 
processes, including tumorigenesis, epithelial 
transmission, proliferation, and cell migration (9). 
On the other hand, Somerville TD and colleagues 
showed that FOXC1 expression increased in at least 
20% of patients with acute myeloid leukemia and 
A B 
C D 
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inhibited monocyte/macrophage differentiation 
(22). In 2014, Pan et al. showed that FOXCUT non-
coding RNA (upstream of the FOXC1 promoter) 
played an important role in carcinogenesis and 
esophageal progression of squamous cells to cancer. 
Experiments were performed on 82 cancer-infected 
tissues compared to non-cancerous tissues (21). It 
was found that a significant increase in expression 
was seen in cancer tissues in FOXC1 and FOXCUT 
(21, 23). In 2016, M. Swaminathan showed that 
FOXC1 plays an important role in AML disease 
onset by regulating HSC by blocking myeloid cell 
differentiation and increasing clonogenic potential. 
In this study, the prognostic value of FOXC1 and a 
factor for disease recurrence or non-response to 
chemotherapy was investigated(24). In 2017, B Han 
et al. showed that FOXC1 plays an important role in 
tumour progression and metastasis in tissue with 
basal cell carcinoma and that FOXC1 expression 
was increased in this type of cancer compared to 
other types of breast cancer (25). Similarly, 
according to the results of the present study, the 
expression of FOXCUT and FOXC1 in all cell 
lines, including Daudi, Ramos, Jurkat, RPMI 8402, 
had a significant increase compared to the control 
sample. Therefore, it seems that a significant 
increase in these two genes in cancer cells can 
increase cell proliferation, cell migration, inhibit 
cell differentiation and enhance tumorigenesis and 
expression of several factors leading to cell 
metastasis. The results of the present study 
somewhat confirm the results of other studies that 
have shown the effect of FOXCUT expression on 
the FOXC1 gene, which ultimately leads to 
increased tumorigenesis in various diseases. It 
seems that these two genes, in addition to the 
malignancies that have been studied in the past, can 
also play an essential role in the development or 
progression of ALL disease. In addition to their role 
in other malignancies, according to the present 
study, these two genes can also proliferate and 
cancer cells in ALL by increasing the expression of 
FOXC1 gene. Therefore, these two genes can be 
considered as therapeutic targets for the treatment 
of this malignancy. 
CCDC26 on chromosome 8 (8q24) is thought to be 
a long non-coding RNA. Despite the ambiguous 
nature of CCDC26, extensive genome analysis has 
shown some evidence of CCDC26 association with 
specific tumors, including glioma and AML. An 
increase in all or part of the CCDC26 genetic locus 
has been observed in children with acute leukemia. 
CCDC26 also appears to control growing myeloid 
leukemia cells by regulating kit expression. In 
2015, Tetsuo Hirano showed that some non-coding 
RNAs, including CCDC26, increased expression in 
acute myeloid leukemia in childhood and showed 
the role of CCDC26 as a tumor suppressor, and also 
showed that decreasing CCDC26 expression 
increased Ckit gene expression.  Also, they found 
that the kit gene plays an important role in tumor 
survival and spread and suggests increasing 
CCDC26 expression, which reduces C-kit 
expression, for treatment in these patients (19). 
According to the data obtained from statistical 
analysis in the study, CCDC26 expression in Daudi 
and Jurkat cell lines has decreased compared to C 
kit as a factor in cancer spread, and CCDC26 
expression has increased compared to Ckit 
expression in Ramos and RPMI 8402. It is possible 
that the expression of CCDC26 could be a factor in 
suppressing the C-kit gene and inhibiting its 
function. Inhibition of the Ckit gene in these cell 
lines reduces cell proliferation, increases apoptosis, 
and decreases drug resistance. This probably 
indicates a link between the two genes, as well as 
the controlling effect that CCDC26 has on the C-kit 
gene. The only study on the effect of CCDC26 gene 
expression on the C-kit gene in the AML cell line 
confirms the findings of the present study, which 
somehow demonstrates the inhibition of C-kit 
function by CCDC26.  
Conclusion 
On the whole, the present study revealed a novel 
lncRNAs network in ALL cells and a new insight 
into ALL treatment. The expression patterns of 
CCDC26 and FOXCUT in Daudi, Ramos, Jurkat, 
RPMI 8402 cell lines could indicate the potential 
role of these non-coding RNAs in regulating the 
biology of this type of leukemia, as CCDC26 shows 
an inhibitory role in cancer cells' growth and 
proliferation, but FOXCUT can play a positive role 
in the proliferation and spread of ALL cells. 
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Therefore, this study provides the first data on the 
expression of these genes in acute lymphoblastic 
leukemia, which is hoped to be the first step in 
further studying these genes in cancers, especially 
leukemias, and will be a starting point for obtaining 
sufficient information to treat patients. 
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